SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)

Completed

Conditions studied: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma

In brief

The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT. The study seeks to understand if different forms of genes result in an increased risk of sores in the mouth and esophagus.

Key facts

Study ID

NCT01402687

Run by

Dana-Farber Cancer Institute

People needed

181

Starts

2010-10-01

Expected to finish

2013-06-01

Last updated by the study team

2013-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have given informed consent to submit a sample of saliva for DNA isolation and SNP analysis
• Have undergone autologous HSCT for treatment of Hodgkin's or non-Hodgkin's lymphoma or multiple myeloma at the Dana-Farber Cancer Institute from 1/1/2006 through 6/30/2010
• Have medical records identifying whether the participants did or did not develop severe mucositis

You may not qualify if…

• Received Palifermin (Kepivance) prior to their conditioning regimen

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.